Chimerix, Inc. announced Thursday that their countermeasure against smallpox, brincidofovir, has seen positive results in animal models.
Chimerix said that animals treated with their smallpox countermeasure showed a significant survival benefit.
"Data from this pivotal study support the potential for brincidofovir to contribute to the U.S. national security and public health preparedness for the treatment of smallpox, which is a Category A Priority Pathogen," Chimerix President and CEO M. Michelle Berrey said. "We look forward to continuing our work with BARDA ( Biomedical Advanced Research and Development Authority) and the FDA (Food and Drug Administration) to advance brincidofovir as a medical countermeasure for smallpox."
The brincidofovir has been shown to have a broad spectrum of activity across five types of viruses, and it is currently in phase three of two clinical trials relating to the cytomegalovirus (CMV) among immunocompromised patients. Chimerix said the antiviral has been given fast-track status in trials for smallpox, CMV and the adenovirus.
Chimerix said BARDA has announced it intended to award a procurement contract with Chimerix for the National Strategic Stockpile. Chimerix also said BARDA is expected to announce the contract by the end of September.
The World Health Organization declared smallpox to be eradicated and samples exist at research facilities in Russia and the U.S. Undocumented samples are suspected to exist elsewhere. Currently no antiviral treatment has been approved for smallpox.